ClinicalTrials.gg
CompletedNCT02564900Updated Jan 22, 2024Results posted

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

A Phase 1 interventional study of DS-8201a (DP1) and DS-8201a (DP2) in Advanced Solid Tumors, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
292
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors.

02

Conditions studied

  • Advanced Solid Tumors

Browse trials for

Keywords

  • Advanced solid tumors
  • phase 1
  • oncology
  • HER2
  • Antibody drug conjugate (ADC)
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 292 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status( PS) of 0 or 1.
  • (LVEF) ≥ 50%

Part 1:

  • Advanced/unresectable or breast cancer or gastric or gastroesophageal junction adenocarcinoma that is to or intolerable with standard treatment, or for which no standard treatment is available.

Part 2a:

  • Advanced breast cancer with overexpression that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.
  • Treated with ado-trastuzumab emtansine (T-DM1)

Part 2b:

  • Advanced gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.
  • Treated with trastuzumab

Part 2c:

  • Advanced breast cancer with HER2 low expression that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.

Part 2d:

  • Satisfy at least one of the following criteria

    1. Advanced/unresectable or metastatic solid malignant tumor with HER2 expression other than breast cancer and gastric or gastroesophageal junction adenocarcinoma that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.
    2. Advanced/unresectable or metastatic tumor with HER2 mutation that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.

Part 2e:

  • Advanced breast cancer with HER2 overexpression that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.
  • Treated with ado-trastuzumab emtansine (T-DM1) (patients with HER2 overexpression only)

Exclusion criteria

Exclusion Criteria:

  • Has a medical history of symptomatic Congestive Heart Failure (CHF) ( classes II-IV) or serious cardiac arrhythmia.
  • Has a medical history of myocardial infarction or unstable angina.
  • Has a prolongation to > 450 millisecond (ms) in males and > 470 ms in females.
  • Has a medical history of lung diseases
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    Part 1 Dose escalation

    Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.

    Drug: DS-8201a (DP1) · Drug: DS-8201a (DP)

  • Experimental
    Part 2 Dose expansion

    Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)

    Drug: DS-8201a (DP1) · Drug: DS-8201a (DP2) · Drug: DS-8201a (DP)

Interventions

  • DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.

  • DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.

  • DS-8201a (DP) is to be administered via intravenous (IV) dose.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)

    Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

Secondary outcomes

  1. Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)

    Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

  2. Best Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)

    Best overall response by independent central review was defined as the proportion of participants who achieved either complete response \[CR\], partial response \[PR\], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

  3. Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

    Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

  4. Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

    Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

  5. Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

    Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

  6. Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

    Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

    Time frame: From 6 months postdose of last participant up to 3 years 5 months

  7. Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose

    The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.

    Time frame: Post first dose up to Day 147

  8. Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose

    The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.

    Time frame: Post first dose up to Day 147

  9. Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose

    The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.

    Time frame: Post first dose up to Day 147

  10. Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose

    The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.

    Time frame: Post first dose up to Day 147

  11. Overview of Treatment-emergent Adverse Events

    Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.

    Time frame: Baseline up to 28 days after the last dose of study drug, up to 3 years 5 months

07

Results

Posted Jun 23, 2021

Participant flow

A total of 292 participants who met all inclusion and no exclusion criteria were enrolled at 8 centers in the US and 6 centers in Japan. A total of 27 participants started the Dose Escalation phase and a total of 265 participants in the Dose Expansion phase.

Dose Escalation
Participant flow — Dose Escalation
MilestoneDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Started333666000000000
Completed000000000000000
Not completed333666000000000
Withdrew: Progressive disease per recist233331000000000
Withdrew: Ongoing100222000000000
Withdrew: Adverse event000113000000000
Dose Expansion
Participant flow — Dose Expansion
MilestoneDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Started000000496220331724182022
Enrolled, but not dosed000000110000001
Completed000000000000000
Not completed000000496220331724182022
Withdrew: Progressive disease per recist00000019178161319101311
Withdrew: Clinical progression0000005120320131
Withdrew: Adverse event00000092201105221
Withdrew: Ongoing00000091011300406
Withdrew: Death000000100010110
Withdrew: Withdrawal by subject000000400010011
Withdrew: Other000000101000001
Withdrew: Did not receive treatment000000110000001

Outcome measures

PrimaryObjective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)

Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)
percentage of participantsDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)0 (0 to 70.8)33.3 (0.8 to 90.6)0 (0 to 70.8)83.3 (35.9 to 99.6)33.3 (4.3 to 77.7)50.0 (11.8 to 88.2)51.0 (36.6 to 65.2)53.7 (41.1 to 66.0)33.3 (14.6 to 57.0)39.4 (22.9 to 57.9)26.3 (9.1 to 51.2)32.0 (14.9 to 53.5)55.6 (30.8 to 78.5)5.0 (0.1 to 24.9)30.4 (13.2 to 52.9)
SecondaryDisease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)

Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)
percentage of participantsDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)100.0 (29.2 to 100.0)100.0 (29.2 to 100.0)66.7 (9.4 to 99.2)100.0 (54.1 to 100.0)100.0 (54.1 to 100.0)100.0 (54.1 to 100.0)88.2 (76.1 to 95.6)95.5 (87.5 to 99.1)85.7 (63.7 to 97.0)87.9 (71.8 to 96.6)78.9 (54.4 to 93.9)88.0 (68.8 to 97.5)83.3 (58.6 to 96.4)80.0 (56.3 to 94.3)82.6 (61.2 to 95.0)
SecondaryBest Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)

Best overall response by independent central review was defined as the proportion of participants who achieved either complete response \[CR\], partial response \[PR\], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Count of participants · Participants
Best Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)
ParticipantsDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Complete response000110280001002
Partial response0104132428713571015
Stable disease32214319281116101451512
Progressive disease001000413343223
Non-evaluable000000220100121
SecondaryDuration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Median · months
Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
monthsDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)12.7 (6.7 to NA)13.6 (7.3 to NA)NA (NA to NA)10.4 (3.4 to NA)5.6 (2.9 to NA)6.9 (3.5 to NA)10.7 (6.9 to 11.5)13.4 (NA to NA)NA (3.0 to NA)
SecondaryTime to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Median · months
Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
monthsDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)2.7 (1.5 to 2.9)2.8 (1.4 to 2.9)2.6 (1.2 to 4.2)2.7 (1.2 to 3.1)1.6 (1.2 to 3.1)2.2 (1.4 to 2.9)1.4 (1.2 to 2.8)3.0 (NA to NA)1.6 (1.2 to 2.9)
SecondaryProgression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Median · months
Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
monthsDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)13.7 (8.5 to 19.6)14.1 (8.5 to NA)NA (2.7 to NA)11.1 (5.0 to NA)4.3 (2.6 to 8.6)8.2 (4.2 to 11.0)11.3 (7.2 to 14.3)4.0 (2.7 to 5.6)11.0 (2.8 to NA)
SecondaryOverall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

Time frame:
From 6 months postdose of last participant up to 3 years 5 months
Reported as:
Median · months
Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)
monthsDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid Tumors
Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)NA (NA to NA)NA (26.4 to NA)NA (NA to NA)19.7 (12.5 to 29.4)18.9 (5.7 to NA)26.2 (10.0 to NA)NA (17.3 to NA)15.6 (4.8 to NA)23.4 (9.7 to NA)
SecondaryPharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose

The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.

Time frame:
Post first dose up to Day 147
Reported as:
Mean · ug*d/mL
Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose
ug*d/mLDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid TumorsDose Expansion: HER2-expressing Breast Cancer
AUClast51.7 ± 13.1116 ± 58.7325 ± 142544 ± 165901 ± 155996 ± 229559 ± 178785 ± 228581 ± 180693 ± 178542 ± 163507 ± 126631 ± 184693 ± 102
AUCinfinity55.0 ± 11.9121 ± 58.9340 ± 150590 ± 1861030 ± 2091100 ± 259602 ± 203848 ± 243589 ± 145762 ± 205596 ± 183563 ± 151683 ± 209753 ± 118
SecondaryPharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose

The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.

Time frame:
Post first dose up to Day 147
Reported as:
Mean · ug/mL
Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose
ug/mLDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid TumorsDose Expansion: HER2-expressing Breast Cancer
Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose22.9 ± 3.7636.2 ± 4.9878.2 ± 16.1127 ± 17.2181 ± 33.1221 ± 41.0126 ± 37.7170 ± 53.6133 ± 18.3155 ± 33.2113 ± 30.0116 ± 21.1150 ± 30.3155 ± 21.4
SecondaryPharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose

The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.

Time frame:
Post first dose up to Day 147
Reported as:
Median · hours
Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose
hoursDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid TumorsDose Expansion: HER2-expressing Breast Cancer
Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose1.95 (1.62 to 1.98)4.03 (1.87 to 4.08)4.12 (1.95 to 6.88)2.02 (1.87 to 2.07)2.06 (1.50 to 3.97)1.97 (1.70 to 6.80)2.00 (1.50 to 6.85)2.08 (1.53 to 7.05)2.16 (1.50 to 7.07)2.00 (1.50 to 6.67)2.03 (1.58 to 4.08)1.95 (1.53 to 7.00)2.02 (1.50 to 7.20)2.05 (1.62 to 7.23)
SecondaryPharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose

The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.

Time frame:
Post first dose up to Day 147
Reported as:
Mean · days
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose
daysDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid TumorsDose Expansion: HER2-expressing Breast Cancer
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose2.18 ± 0.6713.07 ± 1.224.23 ± 1.246.03 ± 0.6037.33 ± 1.646.44 ± 0.7935.52 ± 1.236.00 ± 1.225.28 ± 1.495.79 ± 1.016.18 ± 1.185.90 ± 1.575.61 ± 1.295.46 ± 1.02
SecondaryOverview of Treatment-emergent Adverse Events

Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.

Time frame:
Baseline up to 28 days after the last dose of study drug, up to 3 years 5 months
Reported as:
Count of participants · Participants
Overview of Treatment-emergent Adverse Events
ParticipantsDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid Tumors
Treatment-emergent adverse events (TEAEs)33366650662033192559
Drug-related TEAEs32266650662033182559
TEAEs ≥Grade 300052223421123102037
Drug-related TEAEs ≥Grade 3000322183782081630
Serious TEAEs (including AEs ending in death)00011111173124718
Drug-related serious TEAEs00010041128139
TEAEs associated with death0000003102015
Drug-related TEAEs associated with death0000001102002
TEAEs associated with discontinuation of drug000013722011045
Related TEAEs associated with drug discontinuation000011521011035
TEAEs associated with dose reduction000232518395914
Drug-related TEAEs associated with dose reduction000232418294913
TEAEs associated with dose interruption110643213681391322
Related TEAEs associated with dose interruption100332152871151117

Adverse events

Collected over Treatment-emergent adverse event (TEAE) data were collected from baseline up to 28 days after the last dose of study drug, up to 3 years 5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: Cohort 1, 0.8 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation: Cohort 2, 1.6 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation: Cohort 3, 3.2 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation: Cohort 4, 5.4 mg/kg0/6 (0%)1/6 (16.7%)6/6 (100%)
Dose Escalation: Cohort 5, 6.4 mg/kg0/6 (0%)1/6 (16.7%)6/6 (100%)
Dose Escalation: Cohort 6, 8.0 mg/kg0/6 (0%)1/6 (16.7%)6/6 (100%)
Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg3/50 (6%)11/50 (22%)50/50 (100%)
Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg1/66 (1.5%)17/66 (25.8%)66/66 (100%)
Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg0/21 (0%)3/21 (14.3%)20/21 (95.2%)
Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg0/33 (0%)12/33 (36.4%)33/33 (100%)
Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg1/19 (5.3%)4/19 (21.1%)19/19 (100%)
Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg1/25 (4%)7/25 (28%)25/25 (100%)
Dose Expansion: HER2-expressing Other Solid Tumors5/59 (8.5%)18/59 (30.5%)59/59 (100%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid Tumors
Soft tissue infectionInfections and infestations0/30/30/31/60/60/61/500/660/210/330/190/250/59
Febrile neutropeniaBlood and lymphatic system disorders0/30/30/31/60/60/61/500/661/211/330/190/253/59
Intestinal perforationGastrointestinal disorders0/30/30/30/60/61/60/500/660/210/330/190/250/59
CholangitisHepatobiliary disorders0/30/30/30/61/60/60/500/660/210/330/192/251/59
Decreased appetiteMetabolism and nutrition disorders0/30/30/30/60/60/60/502/660/211/330/193/252/59
PneumoniaInfections and infestations0/30/30/30/60/60/62/500/660/210/332/191/250/59
PneumonitisRespiratory, thoracic and mediastinal disorders0/30/30/30/60/60/63/502/660/213/330/191/251/59
Respiratory failureRespiratory, thoracic and mediastinal disorders0/30/30/30/60/60/64/500/660/211/330/190/251/59
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/30/30/30/60/60/60/501/660/212/330/190/250/59
Platelet count decreasedInvestigations0/30/30/30/60/60/60/504/660/212/330/191/252/59
Most frequent other events
Showing 10 of 165
Most frequent other events
EventDose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing Other Solid Tumors
NauseaGastrointestinal disorders3/31/32/36/64/64/643/5052/6615/2126/3312/1919/2544/59
FatigueGeneral disorders3/30/30/30/63/64/624/5032/6611/219/334/193/2521/59
Decreased appetiteMetabolism and nutrition disorders2/31/31/34/64/62/623/5047/667/2120/338/1922/2535/59
AlopeciaSkin and subcutaneous tissue disorders0/30/31/32/63/63/619/5045/666/2118/334/194/2520/59
HeadacheNervous system disorders2/30/30/30/60/60/68/5011/660/214/334/190/254/59
VomitingGastrointestinal disorders1/31/32/31/64/60/628/5035/6610/2114/333/198/2531/59
ConstipationGastrointestinal disorders0/30/31/34/62/61/618/5030/667/2114/335/197/2516/59
Platelet count decreasedInvestigations0/30/31/34/63/63/615/5024/663/2114/335/1912/2522/59
Neutrophil count decreasedInvestigations0/31/30/34/62/61/612/5025/663/2113/332/1912/2521/59
Electrocardiogram QT prolongedInvestigations2/30/30/31/60/60/65/506/664/211/331/190/251/59

Baseline characteristics

Demographic and baseline characteristics were assessed in the Enrolled Analysis Set (Dose Escalation, n=27; Dose Expansion, n=265).

Age, Categorical
Age, Categorical(Participants)Dose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid TumorsTotal
<=18 years0000000000000000
Between 18 and 65 years2122423348142568121616191
>=65 years1214241614681116646101
Age, Continuous
Age, Continuous(years)Dose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid TumorsTotal
Mean59.3 ± 7.0966.3 ± 4.7348.3 ± 14.5766.8 ± 14.8258.2 ± 10.4066.2 ± 10.6756.2 ± 12.1154.9 ± 10.2857.8 ± 9.6856.3 ± 10.9764.2 ± 11.0066.2 ± 8.5557.4 ± 15.2959.5 ± 9.9058.5 ± 10.1658.1 ± 11.39
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid TumorsTotal
Female33366548622033541399229
Male000001100012205111363
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid TumorsTotal
American Indian or Alaska Native0000001000000001
Asian3336632540623112491714193
Native Hawaiian or Other Pacific Islander0000000100000001
Black or African American0000003211001008
White00000319191275083783
More than one race0000000001100002
Unknown or Not Reported0000001011000014
Region of Enrollment
Region of Enrollment(participants)Dose Escalation: Cohort 1, 0.8 mg/kgDose Escalation: Cohort 2, 1.6 mg/kgDose Escalation: Cohort 3, 3.2 mg/kgDose Escalation: Cohort 4, 5.4 mg/kgDose Escalation: Cohort 5, 6.4 mg/kgDose Escalation: Cohort 6, 8.0 mg/kgDose Expansion: HER2-positive Breast Cancer, 5.4 mg/kgDose Expansion: HER2-positive Breast Cancer, 6.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kgDose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kgDose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kgDose Expansion: HER2-expressing NSCLC TumorsDose Expansion: HER2-expressing Colorectal TumorsDose Expansion: HER2-expressing Other Solid TumorsTotal
United States00000330251611501039112
Japan3336631937422122481713180
08

Study locations

14 sites
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • UC Health Clinical Trials Office
    Cincinnati, Ohio 45229, United States
  • University of Texas M. D. Anderson Cancer Center
    Houston, Texas 77030-3721, United States
  • Aichi Cancer Center Hospital
    Aichi, Japan
  • National Cancer Center Hospital East
    Chiba, Japan
  • Social Medical Corporation Hakuaikai Sagara Hospital
    Kagoshima, Japan
  • Kindai University Hospital
    Osaka, Japan
  • National Cancer Center Hospital
    Tokyo, Japan
  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research
    Tokyo, Japan
09

References and documents

Publications

  • Tsurutani J, Iwata H, Krop I, Janne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Erratum In: Cancer Discov. 2020 Jul;10(7):1078. doi: 10.1158/2159-8290.CD-20-0703. PubMed 32213540 ↗
  • Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Erratum In: Lancet Oncol. 2019 Jun;20(6):e293. doi: 10.1016/S1470-2045(19)30292-X. PubMed 31047803 ↗
  • Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Erratum In: Lancet Oncol. 2019 Jun;20(6):e293. doi: 10.1016/S1470-2045(19)30293-1. PubMed 31047804 ↗
  • Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PubMed 31825192 ↗
  • Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13. PubMed 29037983 ↗
  • Yin O, Iwata H, Lin CC, Tamura K, Watanabe J, Wada R, Kastrissios H, AbuTarif M, Garimella T, Lee C, Zhang L, Shahidi J, LaCreta F. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Clin Pharmacol Ther. 2021 Oct;110(4):986-996. doi: 10.1002/cpt.2291. Epub 2021 Jun 10. PubMed 33999422 ↗
  • Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. PubMed 32058843 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Feb 2019, 41 months.

Results were first posted in Jun 2021, 2 years 4 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 41 months is close to that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2015
First posted
Oct 1, 2015
StartActual
Sep 1, 2015
Primary completionActual
Feb 1, 2019
CompletionActual
Dec 22, 2023
Results first posted
Jun 23, 2021
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02564900
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Sep 1, 2015
Primary completion
Feb 1, 2019
Completion
Dec 22, 2023
Results posted
Jun 23, 2021
Last update
Jan 22, 2024

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion